Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651746 | 0.84 | FGFR1 (0.39) | HPGDFGFR1KDR | |
| SCHEMBL2653470 | 0.84 | GABRA1 (0.43) | HPGDFGFR1KDRGABRA1GABRG2 | |
| SCHEMBL2978010 | 0.83 | ALOX5 (0.48) | ALOX5HPGDFGFR1PRKDCCTSA | |
| SCHEMBL2652694 | 0.82 | HPGD (0.37) | HPGDFGFR1KDRGABRA1GABRG2 | |
| SCHEMBL2970282 | 0.82 | FGFR1 (0.38) | HPGDFGFR1KDR | |
| SCHEMBL2977538 | 0.82 | HPGD (0.37) | HPGDFGFR1KDRGABRA1GABRG2 | |
| SCHEMBL2968478 | 0.81 | ALOX5 (0.48) | ALOX5HPGDFGFR1PRKDCKDR | |
| SCHEMBL2963280 | 0.80 | HPGD (0.37) | HPGDFGFR1KDR | |
| SCHEMBL2977437 | 0.78 | FGFR1 (0.48) | ALOX5HPGDFGFR1GABRA1GABRG2 | |
| SCHEMBL2643152 | 0.77 | GABRA1 (0.38) | FGFR1GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | claimed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | claimed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | GABRB2, GABRB1, GABRB3 | ALOX5 3303/4885HPGD 1855/4885FGFR1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.